Metabolic Side-effects for Second-generation Antipsychotics
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Second-generation antipsychotics (SGAs), including clozapine, are commonly used nowadays as treatment for psychosis. There are increasing concerns about their related metabolic side-effects over weight gain, risks to cause glucose intolerance and hyperlipidemia, and a specific condition known as metabolic syndrome. All these side-effects might be associated with the increased risk of cardiovascular diseases and diabetes mellitus.
This study is to analyze the simple physical measurements (weight and height) and venous blood tests (for fasting blood glucose and lipid) results collected routinely since 2008 (recommended by the local hospital authority as a territory-wide "SGAs Monitoring Program") from those outpatients receiving SGAs (amisulpride, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone) and/or clozapine, at a local psychiatric outpatient clinic in Hong Kong. The investigators hypothesized that there should be differential risks on metabolic side-effects amongst these SGAs.
| Condition |
|---|
|
Mental Disorders |
| Study Type: | Observational |
| Study Design: | Time Perspective: Retrospective |
| Official Title: | Metabolic Side-effects in Patients Receiving Clozapine and Second-generation Antipsychotics in an Outpatient Clinic |
| Estimated Enrollment: | 372 |
| Study Start Date: | November 2010 |
| Estimated Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
SGAs
patients receiving SGAs
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Out-patients in a public psychiatric out-patient centre
Inclusion Criteria:
- was ≥18 years of age
- out-patients
- had received any one of these antipsychotics: aripiprazole, amisulpride, clozapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
- consented to provide physical measurements and venous blood samples
Exclusion Criteria:
- not consented to provide venous blood samples and/or physical measurement
Contacts and Locations| Contact: Albert Kar Kin Chung, MBBS | +852-22556226 | chungkka@hku.hk |
| Hong Kong | |
| Western Psychiatric Centre | Recruiting |
| Hong Kong, Hong Kong, 00000 | |
| Contact: Albert Kar Kin Chung, MBBS +852-22556226 chungkka@hku.hk | |
| Principal Investigator: | Albert Kar Kin Chung, MBBS | Department of Psychiatry, Queen Mary Hospital |
More Information
No publications provided
| Responsible Party: | Chung Kar Kin Albert, Department of Psychiatry, Queen Mary Hospital |
| ClinicalTrials.gov Identifier: | NCT01280396 History of Changes |
| Other Study ID Numbers: | HKCTR-1205 |
| Study First Received: | January 19, 2011 |
| Last Updated: | January 28, 2011 |
| Health Authority: | Hong Kong: Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster |
Keywords provided by The University of Hong Kong:
|
metabolic SGAs clozapine |
Additional relevant MeSH terms:
|
Mental Disorders Psychotic Disorders Schizophrenia and Disorders with Psychotic Features Clozapine Antipsychotic Agents Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Physiological Effects of Drugs Tranquilizing Agents Central Nervous System Depressants Central Nervous System Agents Therapeutic Uses Psychotropic Drugs GABA Antagonists GABA Agents |
ClinicalTrials.gov processed this record on May 22, 2013